NCT07345728

Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies

A Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Donghua Zhang · Academic / Other
• Sex: All
• Age: 18 Years – 78 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single-arm, multi-center, randomized controlled clinical study designed to evaluate the safety and efficacy of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies. A total of 30 subjects are planned to be enrolled.

Conditions

• Relapsed/Refractory B-cell Malignancies

Interventions

Type	Name	Description
DRUG	Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies	Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies

Timeline

• Start date: 2026-01-01
• Primary completion: 2029-06-01
• Completion: 2029-06-01
• First posted: 2026-01-16
• Last updated: 2026-01-16

Locations

1 site across 1 country: China